EXAS vs FDMT · rev $2.76B vs rev $37.0K
EXACT Sciences Corporation (EXAS) versus 4D Molecular Therapeutics Inc (FDMT) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
EXAS currently screens at market cap $20.03B. FDMT currently screens at market cap $518.1M.
Not investment advice. Open the EXAS and FDMT stock pages for the full models.
Not investment advice.